The University of Chicago Header Logo

Connection

Bernard Roizman to Oncolytic Virotherapy

This is a "connection" page, showing publications Bernard Roizman has written about Oncolytic Virotherapy.
Connection Strength

0.589
  1. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor. Gene Ther. 2006 Apr; 13(7):621-9.
    View in: PubMed
    Score: 0.275
  2. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther. 2011 Nov; 18(11):1098-102.
    View in: PubMed
    Score: 0.098
  3. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 2007 Sep 01; 67(17):8301-6.
    View in: PubMed
    Score: 0.076
  4. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):637-46.
    View in: PubMed
    Score: 0.072
  5. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol. 2006 Feb; 80(3):1110-20.
    View in: PubMed
    Score: 0.068
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.